The study authors examined 502 consecutive adult patients who received a high dosage, on average 115 mg, of rhBMP-2, for complex spinal procedures. There were 265 primary and 237 revision procedures with 261 patients receiving an interbody device. There was an average of 11.5 vertebrae instrumented.
The researchers found:
• Interoperative complication rate of 8.2 percent
• Major medical perioperative complication rate of 11.6 percent
• Major perioperative surgical complication rate of 11.6 percent
• Minor medical complication rate of 18.9 percent
• Minor surgical complication rate of 2.6 percent.
• Cancer prevalence of 3.4 percent but no correlation between increasing rhBMP-2 dosage and cancer, radiculopathy or seroma.
More Articles on Spine Surgeons:
8 Strategies for Better Spine Surgeon Documentation—And Why It’s Necessary to Improve
7 Access to Care Issues for Spine Patients & How Surgeons Can Overcome Them
10 Key Components of On-Call Contracts for Spine Surgeons
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
